Molecular Networks and Translational Advances in Renal Fibrosis: Integrating Pathways, Therapeutic Targets, and Regional Perspectives
Authors:
- María José Gavino PinedaMPMaría José Gavino Pineda
- Francisco Luis Díaz RamírezFRFrancisco Luis Díaz Ramírez
- Luz Elena Prieto GarcerantLuz Elena Prieto Garcerant
- Montserrat Ceja CasillasMCMontserrat Ceja Casillas
- Irene Alejandra Apolo FajardoIFIrene Alejandra Apolo Fajardo
- Aleidy Abril Rentería OsorioAOAleidy Abril Rentería Osorio
- Angel Isaias Pandashina MasabandaAMAngel Isaias Pandashina Masabanda
- Mercedes Carolina Freire CapeloMCMercedes Carolina Freire Capelo
Open Access
- 17 November 2025
- journal article
- Published by Quality Consulting Instituto de Educación Capacitación y Certificación de México in IECCMEXICO
- Vol. 3 (1)
Abstract
Renal fibrosis represents the final common pathway of chronic kidney disease (CKD) and remains a major therapeutic challenge worldwide. This review integrates recent mechanistic, translational, and regional evidence to characterize the biological architecture of fibrosis and evaluate emerging therapeutic strategies. Across the literature, a consistent pattern emerges in which TGF-β/Smad3 signaling functions as the central driver of matrix accumulation, epithelial injury, and transcriptional remodeling. This pathway is reinforced by NRF2 dysregulation, oxidative stress, and lipid peroxidation, which amplify inflammatory and fibrogenic responses. Additional mechanisms—including macrophage polarization toward M2-like phenotypes, ferroptotic injury in tubular cells, and extracellular vesicle–mediated transfer of pro-fibrotic molecules—contribute to a self-reinforcing microenvironment that accelerates structural renal decline. Five conceptual figures summarize these interactions, therapeutic frequencies, stage-dependent dynamics, comparative innovation profiles, and the growing participation of Mexico, Colombia, and Ecuador in fibrosis research. Among emerging therapies, NRF2 activation demonstrates the strongest mechanistic support, while mineralocorticoid receptor antagonists remain the most clinically mature option with proven anti-inflammatory and antifibrotic effects. Smad3 and non-coding RNA modulation, exosome-based strategies, ferroptosis inhibition, macrophage reprogramming, and ion-channel targeting represent promising but still evolving approaches. A recurrent finding across publications is that effective antifibrotic therapy will likely require multi-target, stage-adapted combinations capable of modulating oxidative, immune, and transcriptional pathways concurrently. Given the high burden of CKD in Latin America, strengthening regional translational efforts and integrating molecular advances with local epidemiological contexts are essential. Overall, current evidence supports a shift toward precision, multi-modal antifibrotic interventions that address the complex biology of renal fibrosis.Keywords
This publication has 19 references indexed in Scilit:
- Oxidative stress and inflammation in renal fibrosis: Novel molecular mechanisms and therapeutic targetsChemico-Biological Interactions, 2025
- Protecting kidney function: from mechanisms to therapeutic targets and traditional Chinese medicineRenal Failure, 2025
- Ferroptosis and renal fibrosis: mechanistic insights and emerging therapeutic targetsRenal Failure, 2025
- Advances and challenges in kidney fibrosis therapeuticsNature Reviews Nephrology, 2025
- Therapeutic targets of fibrosis: Translational advances and current challengesBritish Journal of Pharmacology, 2023
- Indoxyl sulfate inhibits muscle cell differentiation via Myf6/MRF4 and MYH2 downregulationNephrology Dialysis Transplantation, 2023
- Kidney fibrosis: from mechanisms to therapeutic medicinesSignal Transduction and Targeted Therapy, 2023
- The fibrogenic niche in kidney fibrosis: components and mechanismsNature Reviews Nephrology, 2022
- Mineralocorticoid receptor antagonists in diabetic kidney disease — mechanistic and therapeutic effectsNature Reviews Nephrology, 2021
- LSD1: a viable therapeutic target in cutaneous squamous cell carcinoma?Expert Opinion on Therapeutic Targets, 2020